Skip to main content
2045 search results for:

Osimertinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | Osimertinib | OriginalPaper

    Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

    Lung cancer mortality is the highest among all cancers [ 1 ]. In the past decade, non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletions and exon 21 L858R point mutations, have …

  2. 01-05-2024 | Osimertinib | News

    Osimertinib

    Acquired drug resistance
  3. 01-05-2024 | Osimertinib | News

    Osimertinib

    Pneumonitis
  4. 01-05-2024 | Osimertinib | News

    Osimertinib/Trastuzumab-deruxtecan/Trastuzumab-emtansine

    Various toxicities and lack of efficacy
  5. 01-04-2024 | Osimertinib | News

    Osimertinib/Pemetrexed

    Lack of efficacy and acquired resistance
  6. 01-04-2024 | Osimertinib | News

    Osimertinib

    No improvement
  7. 01-04-2024 | Osimertinib | News

    Osimertinib

    Acquired resistance
  8. 01-04-2024 | Osimertinib | News

    Osimertinib

    Acquired drug resistance
  9. 01-04-2024 | Osimertinib | News

    Osimertinib

    Skin rash and diarrhoea
  10. Open Access 13-04-2024 | Osimertinib | OriginalPaper

    Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

    In patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor ( EGFR ) mutations, compared with first-generation EGFR-tyrosine kinase inhibitors (TKIs), the third-generation EGFR-TKI osimertinib is …

  11. Open Access 01-12-2024 | Osimertinib | OriginalPaper

    circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC)

    Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, but over 70% of patients are already in locally advanced or metastatic stages at the time of diagnosis, depriving them of the opportunity for curative surgical treatment …

  12. 01-03-2024 | Osimertinib | News

    Osimertinib

    Ejection fraction decreased
  13. Open Access 11-03-2024 | Osimertinib | Letter

    Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

    This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, causing cancer cell death and tumor …

  14. 01-02-2024 | Osimertinib | News

    Osimertinib

    Acquired drug resistance
  15. Open Access 27-03-2024 | Osimertinib | Online First

    Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer

    Osimertinib is used as the first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, early dose reduction is often required due to adverse events (AEs). This study aimed to …

  16. 01-01-2024 | Diabetic Nephropathy | News

    Osimertinib

    Rapidly progressive diabetic nephropathy
  17. Open Access 01-12-2024 | Osimertinib | OriginalPaper

    Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum

    In cost-effectiveness analyses of anticancer drugs, partitioned survival models (PSM) and state transition models (STM) are the most common model structures applied for oncology drugs [ 1 ]. PSM has the advantage of simplicity as it directly uses …

  18. Open Access 01-12-2023 | Osimertinib | OriginalPaper

    Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab

    Osimertinib, a third-generation epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI), has emerged as an important treatment for non-small cell lung cancer (NSCLC). Compared to other EGFR-TKIs, Osimertinib has been associated with …

  19. Open Access 01-12-2023 | NSCLC | OriginalPaper

    Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

    Molecularly targeted therapies have emerged as essential treatment modalities for non-small cell lung cancer (NSCLC). Somatic mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain have been reported as definitive …

  20. 01-12-2023 | Osimertinib | News

    Osimertinib

    Reactivation of cytomegalovirus manifested as cytomegalovirus pneumonia

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.